IDSA News - June 2015  (Plain Text Version)

Return to Graphical Version

 

In this issue:
PATIENT CARE AND SCIENCE
•  FDA Cautions About Dose Confusion and Medication Errors for Antibacterial Drug Zerbaxa
•  Foundation to Develop Database of C. difficile Providers
CLINICAL PRACTICE MANAGEMENT
•  So Long SGR! What’s Next, and How Will MACRA Affect You?
•  CMS Proposes Changes to Meaningful Use Program; ONC Updates HIT Certification Criteria
•  IDSA Offers Discussion Board, Other Resources on Contract Negotiations
POLICY AND ADVOCACY
•  IDSA Members Urge Increased NIH Funding on Capitol Hill
•  Help HIVMA Advocate for HIV Funding and Syringe Exchange
•  HOPE Act Springs Forward
•  Weigh in on FDA Proposed Changes to Blood Donor Deferral Policy
•  Societies Provide Comments to NIH on Improving Impact and Sustainability of Biomedical Research
GLOBAL ID
•  Science Speaks: Global HIV, TB and Ebola Research and Responses
EDUCATION AND RESOURCES
•  IDSA Foundation Joins the Combined Federal Campaign
•  Courses in Antimicrobial Stewardship
•  Updated Lyme Disease Case Study Course
YOU AND YOUR COLLEAGUES
•  Reminder: CID Editor-in-Chief Search is On!
•  Members on the Move
•  Member Report
FROM THE PRESIDENT
•  Concerned About Changes to the ABIM MOC Program? IDSA is Working for You
TOP STORIES
•  Big Advances in Antibiotic Stewardship and R&D Policies
•  MERS: The Emergence Continues -- Learn the Latest at IDWeek
•  Thank You From IDSA
•  Journal Club

 

FDA Cautions About Dose Confusion and Medication Errors for Antibacterial Drug Zerbaxa

The U.S. Food and Drug Administration (FDA) issued a warning last month about the risk for dosing errors with the antibacterial drug Zerbaxa (ceftolozane and tazobactam) due to confusion about the drug strength displayed on the vial and carton labeling. To prevent future medication errors, the strength on the drug labeling has been revised to reflect the sum of the two active ingredients. Zerbaxa is used to treat complicated infections in the urinary tract, or in combination with the antibacterial drug metronidazole to treat complicated infections in the abdomen. Click here for an FDA Drug Safety Podcast on these cautions (MP3 - 1.8MB).

IDSA offers two email services to help members stay informed of updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:

Updated Information and Guidelines for Evaluation of Patients for MERS-CoV Infection ( CDC Alert 06/12/2015)
Bird Infections with Highly Pathogenic Avian Influenza A (H5N2), (H5N8), and (H5N1) Viruses: Recommendations for Human Health Investigations and Response (CDC Alert 6/2/15)
Lassa Fever Confirmed in Death of U.S. Traveler Returning from Liberia (CDC Alert 5/26/15)
Outbreak of Recent HIV and HCV Infections Among Persons Who Inject Drugs (CDC Alert 4/24/15)

IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)

Is Your Facility Experiencing Antibiotic Shortages?
IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at schang@idsociety.org.